Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases

Expert Opinion on Drug Discovery

Volumn 3, Issue 9, 2008, Pages 1041-1065

  Bonfils, Claire ^a   Walkinshaw, Donald R ^b,c   Besterman, Jeffrey M ^a   Yang, Xiang Jiao ^b,c   Li, Zuomei ^a  

^a METHYLGENE INC   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Belinostat; Clinical development; HDAC; HDAC inhibitors; Inflammatory diseases; MGCD0103; Neurodegenerative diseases; Oncology; Panobinostat; Romidepsin; SNDX 275; Vorinostat

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BEXAROTENE; BORTEZOMIB; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; ISOTRETINOIN; ITF 2357; JNJ 16241199; MGCD 01303; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PACLITAXEL; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; PREDNISONE; R 306465; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RILUZOLE; ROMIDEPSIN; SNDX 275; TAMOXIFEN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; AMYOTROPHIC LATERAL SCLEROSIS; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APRAXIA; ATAXIA; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BRAIN ISCHEMIA; BREAST CANCER; CARDIOTOXICITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFUSION; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DEGENERATIVE DISEASE; DEHYDRATION; DEMENTIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ECG ABNORMALITY; ENTERITIS; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HUNTINGTON CHOREA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; INFLAMMATORY DISEASE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PARALYTIC ILEUS; PERIPHERAL EDEMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTHROMBIN TIME; PRURITUS; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOMNOLENCE; SPINAL MUSCULAR ATROPHY; THROMBOCYTOPENIA; UNSTEADINESS; VOMITING;

EID: 52649169923     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.9.1041     Document Type: Review

References (171)

1. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 2000;19(6):1176-9
2. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007;26(37):5310-8
3. Kim SC, Sprung R, Chen Y, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006;23(4):607-18
4. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 1964;51:786-94
5. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9(3):206-18
6. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338(1):17-31
7. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007;404(1):1-13
8. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003;133(7 Suppl):2485S-2493S
9. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265(28):17174-9
10. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiadon inhibits histone deacetylases. Proc Natl Acad Sci USA 1998;95(6):3003-7
11. Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs 2008;9(4):371-8
12. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26(37):5541-52
13. Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12(10):1247-52
14. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26(9):1351-6
15. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25(1):84-90
16. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16(7):1111-20
17. Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 2007;43(9):585-99
18. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9(10 Pt 1):3578-88
19. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060-6
20. Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2008;109(2):182-6
21. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008;26(1):81-7
22. Vansteenkiste J, Cutsem EV, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008
23. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19(5):964-9
24. Kirschbaum MH, Goldman BH, Zain JM, et al. Vorinostat (Suberoylanilide hydroxamic acid) in relapsed or refractory hodgkin lymphoma: SWOG 0517 49th ASH Annual Meeting. Blood 2007;110(11) [abstract 2574]
25. Richardson PG, Mitsiades CS, Colson K, et al. Final results of a phase I Trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma 49th ASH Annual Meeting. Blood 2007;110(11) [abstract 1179]
26. Kirschbaum MH, Zain JM, Popplewell L, et al. A phase 2 study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in relapsed or refractory indolent non hodgkin lymphoma. A California Cancer Consortium Study 49th ASH Annual Meeting. Blood 2007;110(11) [abstract 2568]
27. ClinicalTrials.gov - a service of the U.S. National Institutes of Health. Available from: www.clinicaltrials.gov [cited 2008 May 01]
28. Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007;13(12):3605-10
29. Hymes K, Dummer R, Sterry W, et al. Phase I trial of oral vorinostat in combination with bexarotene in patients with advanced cutaneous T-cell lymphoma. ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 8613]
30. Badros AZ, Philip S, Niesvizk R, et al. Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts). ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 8548]
31. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral hiscone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the Phase I trial: A New York Cancer Consortium. ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 7000]
32. Munster PN, Lacevic M, Schmitt M, et al. Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy. ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 3501]
33. Nakajima H, Kim YB, Terano H, et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241(1):126-33
34. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62(17):4916-21
35. Yurek-George A, Cecil AR, Mo AH, et al. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. J Med Chem 2007;50(23):5720-6
36. Piekarz R, Frye R, Wright J, et al. Update of the NC1 multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. 43rd ASCO Annual Meeting; 2007. J Clin Oncol 2007;18S [abstract 8027]
37. Kim YH, Reddy S, Kim EJ, et al. Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL: An International, Multicenter Study. 49th ASH Annual Meeting. Blood 2007;110(11) [abstract 123]
38. Lerner A, Demierre M-F, Whittaker S, et al. Romidepsin (Depsipeptide, FK228) induces clinically significant responses in treatment-refractory CTCL: Interim Report of a Phase II Multicenter Study. 48th ASH Annual Meeting. Blood 2006;108(11) [abstract 2468]
39. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12(12):3762-73
40. Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008;14(1):188-98
41. Stadler WM, Margolin K, Ferber S, et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006;5(1):57-60
42. Haigentz M Jr, Adrien LR, Belbin TJ, et al. Translational studies of depsipeptide (romidepsin, FK228), a Histone Deacetylase (HDAC) inhibitor, in patients with head and neck cancer [abstract 3524]. 98th AACR Annual Meeting. Proc Am Assoc Cancer Res 2007
43. Molife R, Patterson S, Riggs C, et al. Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC) [abstract 14554]. 42nd ASCO Annual Meeting. J Clin Oncol 2006;24(18S) [abstract 5152]
44. Piekarz R, Luchenko V, Draper D, et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 3571]
45. Doss HH, Jones SF, Infante JR, et al. A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 2567]
46. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409(2):581-9
47. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006;12(2):634-42
48. Prince HM, George D, Patnaik A, et al. Phase I study of oral LBH589, a novel Deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma. 43rd ASCO Annual Meeting; Chicago, IL. J Clin Oncol 2007;25(18S) [abstract 3500]
49. Spencer A, Prince M, DeAngelo DJ, et al. Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), ADMINISTERED on 2 schedules, in patients with advanced hematologic malignancies. 49th ASH Annual Meeting. Blood 2007;110(11) [abstract 907]
50. Duvic M, Vanaclocha F, Bernengo MG, et al. Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL). ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 8555]
51. Rathkopf DE, Wong BY, Ross RW, et al. A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC). 2008 ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 5152]
52. Moradei O, Vaisburg A, Martell RE. Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type inhibitors. Curr Top Med Chem 2008; In press
53. Zhou N, Moradeia O, Raeppel S, et al. Design and Synthesis of Arylamino-(2-aminophenyl)-Benzamides or Cinnamides (A) and Heteroaryl-N-(2-aminophenyl)-Benzamides (B) as a Novel Class of Histone Deacetylase Inhibitors 232nd ACS National Meeting; 2006; San Francisco, CA
54. Vaisburg A. Discovery and development of MGCD0103 - an orally active HDAC inhibitor in human clinical trials. XIXth International Symposium on Medicinal Chemistry; 2006; Istanbul, Turkey
55. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol cancer ther 2008;7(4):759-68
56. Nguyen H, Gravel S, MacLeod AR. Synergistic antitumor activity of the isotype-selective histone deacetylase inhibitor MGCD0103 in combination with gemcitabine. AACR-NCI-EORTC; 2005; Philadelphia, PA
57. Fujita H, Murakami K, Nameki D, et al. MGCD0103, an oral isotype-selective HDAC inhibitor, significantly enhances the anti-tumor efficacy of Taxane via the unique modulation of angiogenesis gene expressions [abstract 2446]. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; AACR Annual Meeting; 2008; San Diego, CA
58. Siu LL, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26(12):1940-7
59. Carducci M, Siu LL, Sullivan R, et al. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. 42nd ASCO Annual Meeting. J Clin Oncol 2006;24(18S) [abstract 3007]
60. Gelmon K, Tolcher A, Carducci M, et al. Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors [abstract 3147]. 41st ASCO Annual Meeting 2005. J Clin Oncol 2005
61. Garcia-Manero G, Assouline S, Cortes J, et al. Phase I study of the oral isotype-specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008; In press
62. Lancet JE, Nichols G, Assouline S, et al. A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS). 43rd ASCO Annual Meeting. J Clin Oncol 2007;25(18S) [abstract 2516]
63. Garcia-Manero G, Minden M, Estrov Z, et al. Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS). 42nd ASCO Annual Meeting. J Clin Oncol 2006;24(18S) [abstract 6500]
64. Bonfils C, Kalita A, Dubay M, et al. Evaluation of the pharmacodynamic: effects of MGCD0103 from preclinical models to human, using a novel HDAC enzyme assay. Clin Cancer Res 2008;14(11):3441-9
65. Siu LL, Carducci M, Patterson T, et al. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as a three-times weekly oral dose in patients with advanced solid tumors. 18th EORTC-NCI-AACR. Eur J Cancer Suppl 2006;94-5
66. Bociek RG, Kuruvilla J, Pro B, et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). 2008 ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 8507]
67. Crump M, Andreadis C, Assouline S, et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study [abstract 8528]. 2008 ASCO Annual Meeting; 2008; Chicago. J Clin Oncol 2008;26 [abstract 8507]
68. Garcia-Manero G, Yang AS, Klimek V. et al. Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). 49th ASH Annual Meeting. Blood 2007;110(11) [abstract 444]
69. Garcia-Manero G, Yang AS, Klimek V, et al. Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). 43rd ASCO Annual Meeting. J Clin Oncol 2007;25(18S) [abstract 7062]
70. Garcia-Manero G, Yang AS, Giles F, et al. Phase I/II study of the oral isotype-selective Histone Deacetylase (HDAC) inhibitor MGCD0103 in combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML). 48th ASH Annual Meeting. Blood 2006;108(11) [abstract 1954]
71. Hurwitz H, Nelson B, O'Dwyer PJ, et al. Phase I/II: the oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. 2008 ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 4625]
72. Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14(3):804-10
73. Kelly WK, Yap T, Lee J, et al. A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors. 43rd ASCO Annual Meeting. J Clin Oncol 2007;25(18S) [abstract 14092]
74. Advani R, Hymes K, Pohlman B, et al. Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma: results of a phase II study. 49th ASH Annual Meeting. Blood 2007;110(11) [abstract 3453]
75. Mackay H, Hirte HW, Covens A, et al. A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial. 2008 ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 5518]
76. Sullivan D, Singhal S, Schuster M, et al. A phase II study of PXD101 in advanced multiple myeloma. 48th ASH Annual Meeting. Blood 2006;108(11) [abstract 3583]
77. Northfelt DW, Marschke RF, Bonnem E, et al. A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors. 43rd ASCO Annual Meeting. J Clin Oncol 2007;25(18S) [abstract 3501]
78. Odenike O, Green M, Larson RA, et al. Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms. ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 7057]
79. Finkler NJ, Dizon DS, Braly P, et al. Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC) [abstract 5519]. ASCO Annual Meeting; Chicago. J Clin Oncol 2008;26 [abstract 5519]
80. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases - the development of an anticancer agent. Int J Biochem Cell Biol 2007;39(7-8):1388-405
81. Kummar S, Gutierrez M, Gardner ER, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007;13(18 Pt 1):5411-7
82. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23(17):3912-22
83. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109(7):2781-90
84. Hauschild A, Trefter U, Garbe C, et al. A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. 42nd ASCO Annual Meeting; Atlanta, GA. Proc Am Soc Clin Oncol 2006;24(18S) [abstract 8044]
85. Gore SD, Jiemjit A, Silverman LB, et al. Combined methyltransferase/ histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage. 48th ASH Annual Meeting; Orlando, FL. Blood 2006;108(11) [abstract 517]
86. Pili R, Rudek M, Altiok S, et al. Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors. 42nd ASCO Annual Meeting; Atlanta, GA. Proc Am Soc Clin Oncol 2006;24(18S) [abstract 3055]
87. Golay J, Cuppini L, Leoni F, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007;21(9):1892-900
88. Buggy JJ, Cao ZA, Bass KE, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 2006;55:1309-17
89. Balasubramanian S, Ramos J, Sirisawad M, et al. Sensitivity of primary hematopoietic tumors and tumor lines to the novel HDAC inhibitor PCI-24781. 43th ASCO Annual Meeting. J Clin Oncol 2007;;25(18S) [abstract 14062]
90. Arts J, Angibaud P, Marien A, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 2007;97(10):1344-53
91. Barbetti V, Gozzini A, Rovida E, et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ ETO-positive cells. Oncogene 2008;27(12):1767-78
92. Glauben R, Batra A, Stroh T, et al. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut 2008;57(5):613-22
93. Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005;11(1-12):1-15
94. Galli M, Salmoiraghi S, Golay J, et al. A phase II multiple dose clinical trial of Histone Deacetylase Inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results [abstract 1175]. ASH Meeting. Blood 2007
95. Viviani S, Bonfante V, Fasola C, et al. Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients [abstract 8532]. ASCO Annual Meeting; Chicago. J Clin Oncol 2008
96. Fong PC, Settatree S, Sinha R, et al. A first-in-man phase I study of R306465, a histone deacetylase (HDAC) inhibitor exploring pharmacokinetics (PK) and pharmacodynamics (PD) utilizing an electrochemiluminescent immunoassay in patients (p) with advanced tumours [abstract 3578]. ASCO Annual Meeting Proceedings Part I; ASCO Annual Meeting. J Clin Oncol 2007
97. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003;8(5):707-17
98. Mori H, Abe F, Furukawa S, et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC) II. Biological activities in animal models. J Antibiot 2003;56(2):80-6
99. Nishida K, Komiyama T, Miyazawa S, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004;50(10):3365-76
100. Lin HS, Hu CY, Chan HY, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007;150(7):862-72
101. Nasu Y, Nishida K, Miyazawa S, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 2008;16(6):723-32
102. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004;101(11):3921-26
103. Leng C, Gries M, Ziegler J, et al. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 2006;34(6):776-87
104. Mishra N, Reilly CM, Brown DR, et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003;111(4):539-52
105. Reilly CM, Mishra N, Miller JM, et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004;173(6):4171-8
106. Li N, Zhao D, Kirschbaum M, et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci USA 2008;105(12):4796-801
107. Glauben R, Batra A, Fedke I, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006;176(8):5015-22
108. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007;13(11):1299-307
109. Matsuoka H, Fujimura T, Unami A, et al. Novel method for selecting immunosuppressive histone deacetylase (HDAC) inhibitors with minimal thrombocytopenia. Biol Pharm Bull 2008;31(2):305-8
110. Matsuoka H, Unami A, Fujimura T, et al. Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 2007;571(2-3):88-96
111. Saba RN, Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 2006;13(4):539-50
112. Sadri-Vakili G, Bouzou B, Benn CL, et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet 2007;16(11):1293-306
113. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413(6857):739-43
114. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003;100(4):2041-6
115. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003;23(28):9418-27
116. Gauthier LR, Charrin BC, Borrell-Pages M, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004;118(1):127-38
117. Dompierre JP, Godin JD, Charrin BC, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 2007;27(13):3571-83
118. Patzke H, Chesworth R, Li Z, et al. Discovery and development of novel HDAC inhibitors for huntington's disease. Huntingon Disease Clinical Research Symposium; Boston, MA. Neurotherapeutics 2007:371
119. En Vivo Pharmaceuticals' Programs. Available from: http://www.envivopharma.com/template/5_5_1.html [cited 2008 May 01]
120. Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001;98(17):9808-13
121. Tsai LK, Tsai MS, Lin TB, et al. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis 2006;24(2):286-95
122. Winberg M, El-Khodor BF, Ramboz S, et al. Beneficial effects of valproic acid and hydroxyurea in a mouse model of Spinal Muscular Atrophy (SMA). 59th Annual Meeting of the American Academy of Neurology; Montreal, Que, Canada. 2007:SC01-001
123. Avila AM, Burnett BG, Taye AA, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007;117(3):659-71
124. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006;67(3):500-1
125. Rouaux C, Jokic N, Mbebi C, et al. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 2003;22(24):6537-49
126. Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005;93(5):1087-98
127. Petri S, Kiaei M, Kipiani K, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2006;22(1):40-9
128. Gray SG, Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 2006;1(2):67-75
129. Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 2007;62(4):314-26
130. Camelo S, Iglesias AH, Hwang D, et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2005;164(1-2):10-21
131. Faraco G, Pancani T, Formentini L, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006;70(6):1876-84
132. Yildirim F, Gertz K, Kronenberg G, et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol 2008;210(2):531-42
133. Ren M, Leng Y, Jeong M, et al. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004;89(6):1358-67
134. Bredy TW, Wu H, Crego C, et al. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learning & memory (Cold Spring Harbor, NY). 2007;14(4):268-76
135. Bredy TW, Barad M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learning & memory (Cold Spring Harbor, NY). 2008;15(1)39-45
136. Fischer A, Sananbenesi F, Wang X, et al. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007;447(7141):178-82
137. Francis YI, Fa M, Ashraf H, et al. Beneficial effect of the histone deacetylase inhibitor TSA in a mouse model of Alzheimer's disease [abstract 548.5]. San Diego. Soc Neurosci 2007
138. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr opin pharmacol 2008;8(1):57-64
139. Cao H, Jung M, Stamatoyannopoulos G. Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce gamma gene expression in vivo. Exp Hematol 2005;33(12):1443-9
140. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005;366(9485):549-55
141. Minetti GC, Colussi C, Adami R, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006;12(10):1147-50
142. Berry JM, Cao DJ, Rothermel BA, Hill JA. Histone deacetylase inhibition in the treatment of heart disease. Expert Opin Drug Saf 2008;7(1):53-67
143. Kee HJ, Sohn IS, Nam KI, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006;113(1):51-9
144. Kong Y, Tannous P, Lu G, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006;113(22):2579-88
145. Kitagawa Y, Tamura Y, Shimizu J, et al. Effects of a novel histone deacetylase inhibitor, N-(2-aminophenyl) benzamide, on a reversible hypertrophy induced by isoproterenol in in situ rat hearts. J Pharmacol Sci 2007;104(2):167-75
146. Trivedi CM, Luo Y, Yin Z, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007;13(3):324-31
147. Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002;110(4):479-88
148. Akache B, Nguyen DT, Campeol N, Georgopapadakou NH. MG3290,a Selective Histone Deacetylase (HDAC) inhibitor, potentiates the anticandidal activity of ergosterol synthesis inhibitors, but not of compounds with other mechanisms of action [abstract A-114]. American Society of Microbiology General Meeting. Proceedings of the ASM; 2007
149. Nguyen DT, Yeung B, Akache B, Georgopapadakou NH. MG3290, a Selective Histone Deacetylase (HDAC) inhibitor, increases the post-antifungal effect and cidal potential of Azoles in Candida species and decreases the frequency of Azole resistance in Candida glabrata [abstract A-113]. American Society of Microbiology General Meeting. Proceedings of the ASM; 2007
150. MethylGene: research & development; Histone Deacetylases (HDAC) Non-Oncology. Available from: http://www.methylgene.com/ content.asp?node=163 [cited 2008 May 01]
151. Diekema DJ, Messer SA, Georgopapadakou NH, Pfaller MA. Synergy of MGCD290, a histone deacetylase inhibitor, with Azole antifungals tested against clinical isolates of Candida and Aspergillus [abstract M-1822]. 47th Annual ICAAC Conference; 2007
152. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer lett 2008; In press (doi:10.1016):J.Can Let. 2008-03.037
153. Venturelli S, Armeanu S, Pathil A, et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007;109(10):2132-41
154. Bao R, Qu H, Wang D, et al. Anti-tumor activity of CUDC-101, a novel small molecule inhibitor of HDAC, EGFR and Her2, in hepatocellular
155. Tavera-Mendoza LE, Quach TD, Dabbas B, et al. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proc Natl Acad Sci USA 2008;105(24):8250-5
156. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007;25(26):4051-6
157. Munshi A, Tanaka T, Hobbs ML, et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol cancer ther 2006;5(8):1967-74
158. Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64(1):316-21
159. Geng L, Cuneo KC, Fu A, et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006;66(23):11298-304
160. Lopez CA, Feng FY, Herman JM, et al. Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. Int J Radiat Oncol Biol Phys 2007;69(1):214-20
161. Flatmark K, Nome RV, Folkvord S, et al. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat oncol (London,England) 2006;1:25
162. Kim IA, Shin JH, Kim IH, et al. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 2006;12(3 Pt 1):940-9
163. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102(24):8567-72
164. Saji S, Kawakami M, Hayashi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005;24(28):4531-9
165. Moradei OM, Mallais TC, Frechette S, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem 2007;50(23):5543-6
166. Methot JL, Chakravarty PK, Chenard M, et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008;18(3):973-8
167. LEO Pharma In-Licenses Worldwide Rights for Preclinical HDAC Inhibitor from Topo Target and CuraGen. 2006. Available from: http://www.leo-pharma.com/41256A84002BE7FC/0/ DCB86FFC6D57147CC125721A00501415?OpenDocument [cited 2008 Jun 10]
168. Hellberg PE; Inventor Alcon, Inc., applicant. Histone deacetylase inhibitors for treating degenerative diseases of the eye. USA patent WO/ 2004/043348; 2004
169. Hancock WW, Wang L, de Zoeten EF, et al. HDAC6 is a key new epigenetic target for the enhancement of Treg production and function in vitro and in vivo [abstract 168]. American Transplant Congress; Toronto. ATC Proceedings; 2008
170. Renthal W, Maze I, Krishnan V, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007;56(3):517-29
171. Tsankova NM, Berton O, Renthal W, et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006;9(4):519-25;24(18S) [abstract 3007]